Neoadjuvant chemotherapy in fertility-sparing management of FIGO 2018 stage IB2 cervical cancer
Int J Gynecol Cancer
.
2022 May 3;32(5):680-685.
doi: 10.1136/ijgc-2021-003293.
Authors
Claire Sanson
1
,
François Zaccarini
1
,
Michael Majer
2
,
Patricia Pautier
3
,
Catherine Genestie
4
,
Cyrus Chargari
5
,
Sebastien Gouy
1
,
Philippe Morice
6
Affiliations
1
Department of Gynecological Surgery, Gustave Roussy, Villejuif, Île-de-France, France.
2
Department of Radiology, Gustave Roussy, Villejuif, Île-de-France, France.
3
Department of Medical Oncology, Gustave Roussy, Villejuif, Île-de-France, France.
4
Department of Pathology, Gustave Roussy, Villejuif, Île-de-France, France.
5
Department of Radiation Oncology, Gustave Roussy, Villejuif, Île-de-France, France.
6
Department of Gynecological Surgery, Gustave Roussy, Villejuif, Île-de-France, France philippe.morice@gustaveroussy.fr.
PMID:
35504625
DOI:
10.1136/ijgc-2021-003293
No abstract available
Keywords:
cervical cancer; gynecologic surgical procedures.
MeSH terms
Cervix Uteri
Chemotherapy, Adjuvant
Female
Fertility
Humans
Neoadjuvant Therapy*
Uterine Cervical Neoplasms* / drug therapy